First Midwest Bank Trust Division boosted its stake in Eli Lilly and Company (NYSE:LLY) by 5.5% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 60,323 shares of the company’s stock after acquiring an additional 3,154 shares during the quarter. First Midwest Bank Trust Division’s holdings in Eli Lilly and were worth $5,160,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in LLY. Advantus Capital Management Inc grew its position in shares of Eli Lilly and by 0.4% during the first quarter. Advantus Capital Management Inc now owns 97,698 shares of the company’s stock worth $8,217,000 after buying an additional 425 shares in the last quarter. Modera Wealth Management LLC purchased a new stake in shares of Eli Lilly and during the 1st quarter valued at about $238,000. Partnervest Advisory Services LLC raised its holdings in shares of Eli Lilly and by 12.4% during the 1st quarter. Partnervest Advisory Services LLC now owns 5,820 shares of the company’s stock valued at $489,000 after buying an additional 643 shares during the period. Stephens Inc. AR raised its holdings in shares of Eli Lilly and by 4.5% during the 1st quarter. Stephens Inc. AR now owns 44,023 shares of the company’s stock valued at $3,703,000 after buying an additional 1,901 shares during the period. Finally, Bellevue Group AG raised its holdings in shares of Eli Lilly and by 275.4% during the 1st quarter. Bellevue Group AG now owns 131,400 shares of the company’s stock valued at $11,052,000 after buying an additional 96,400 shares during the period. 76.43% of the stock is currently owned by hedge funds and other institutional investors.
Eli Lilly and Company (LLY) traded down $0.74 on Thursday, hitting $85.32. The stock had a trading volume of 3,130,900 shares, compared to its average volume of 3,670,362. The company has a market cap of $94,760.24, a P/E ratio of 21.04, a PEG ratio of 1.89 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $66.39 and a 52 week high of $89.09. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The firm’s revenue was up 9.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.88 EPS. research analysts predict that Eli Lilly and Company will post 4.21 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.44%. Eli Lilly and’s dividend payout ratio is presently 98.58%.
Several equities research analysts have issued reports on the company. BMO Capital Markets set a $73.00 price objective on Eli Lilly and and gave the stock a “sell” rating in a report on Tuesday. Jefferies Group restated a “buy” rating and set a $89.00 price objective on shares of Eli Lilly and in a report on Thursday, August 31st. Leerink Swann lifted their price objective on Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a report on Monday, October 23rd. Piper Jaffray Companies reiterated an “overweight” rating and issued a $105.00 target price (up previously from $103.00) on shares of Eli Lilly and in a research report on Friday, September 8th. Finally, BidaskClub lowered Eli Lilly and from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Three analysts have rated the stock with a sell rating, seven have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $90.25.
In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $86.18, for a total value of $3,152,895.30. Following the completion of the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 628,588 shares of company stock valued at $53,399,536 in the last three months. 0.20% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Eli Lilly and Company (LLY) Shares Bought by First Midwest Bank Trust Division” was originally published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.thestockobserver.com/2017/12/07/eli-lilly-and-company-lly-shares-bought-by-first-midwest-bank-trust-division.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.